Daniel Stiglitz
Alnylam Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Blood Pressure and Hypertension Studies, Receptor Mechanisms and Signaling, Eicosanoids and Hypertension Pharmacology, Anesthesia and Pain Management, Pain Mechanisms and Treatments
Most-Cited Works
- → RNA Interference With Zilebesiran for Mild to Moderate Hypertension(2024)107 cited
- → Intraoperative Nitrous Oxide as a Preventive Analgesic(2010)25 cited
- → Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension(2025)19 cited
- → ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HYPERTENSION INADEQUATELY CONTROLLED WITH A STANDARD ANTIHYPERTENSIVE MEDICATION: EFFICACY AND SAFETY RESULTS FROM THE KARDIA-2 STUDY(2024)9 cited
- → Abstract 116: Safety And Tolerability Of Zilebesiran, An RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, In Obese Patients With Hypertension(2023)4 cited
- → Subgroup results from KARDIA-2: impact of demographic and baseline disease characteristics on zilebesiran response in patients with hypertension uncontrolled by a standard oral antihypertensive(2024)2 cited
- → CONSISTENT ANTIHYPERTENSIVE EFFICACY OF THE RNA INTERFERENCE THERAPEUTIC ZILEBESIRAN: SUBGROUP RESULTS FROM THE KARDIA-1 PHASE 2 STUDY IN PATIENTS WITH HYPERTENSION(2024)1 cited
- → 26-A-15266-ACC POOLED SAFETY ANALYSIS OF ZILEBESIRAN, AN INVESTIGATIONAL LONG-ACTING RNA INTERFERENCE THERAPEUTIC, FROM PHASE 2 STUDIES IN PATIENTS WITH HYPERTENSION(2026)
- → Development and Validation of ‘Patient Optimizer’ (POP) Algorithms for Predicting Surgical Risk with Machine Learning(2022)